Will Cardinal Health’s (CAH) Specialty Growth and Higher FCF Guidance Reshape its Capital Return Narrative

• Earlier this week, Cardinal Health reported that quarterly revenue rose 11% year on year to US$60.94 billion, missing analysts’ revenue forecasts but beating full-year earnings-per-share guidance.
• Management highlighted the durability and resilience of the business, pointing to growth in its specialty portfolio, stronger free cash flow guidance for fiscal 2026, and ongoing share repurchases as key supports for its longer-term outlook.
• With Cardinal Health boosting free cash flow guidance and emphasizing specialty growth, we’ll now consider how this affects the existing investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Cardinal Health Investment Narrative Recap

To own Cardinal Health, you need to believe in its role as a critical, scale-driven distributor that can convert huge, low-margin revenue into steady cash generation. The latest quarter supports that narrative on earnings and free cash flow, even though revenue missed expectations and the stock reaction was muted. In my view, the most important near-term catalyst remains how effectively Cardinal translates specialty growth into stronger cash flows, while the biggest risk is ongoing government pricing and reimbursement pressure. The new results do not materially change either.

Among recent announcements, the upgrade to free cash flow guidance for fiscal 2026 stands out as most relevant. It reinforces management’s confidence in funding both infrastructure investment and capital returns, including US$1.73 billion of share repurchases completed to date. For investors watching the catalysts, this raised cash flow outlook sits directly against regulatory and reimbursement uncertainties that could pressure margins if conditions tighten further.

Yet behind the higher free cash flow guidance and share repurchases, investors should be aware of the potential impact of changing government reimbursement and pricing programs on...

Read the full narrative on Cardinal Health (it's free!)

Cardinal Health's narrative projects $314.4 billion revenue and $2.3 billion earnings by 2029. This requires 7.8% yearly revenue growth and about a $0.7 billion earnings increase from $1.6 billion today.

Uncover how Cardinal Health's forecasts yield a $245.27 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently estimate Cardinal Health’s fair value between US$245 and US$466 per share, a wide span of individual views. Set this against the risk that tighter government pricing and reimbursement could pressure margins, and it becomes even more important to compare several independent opinions on the company’s prospects.

Explore 3 other fair value estimates on Cardinal Health - why the stock might be worth just $245.27!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cardinal Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 27 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com